Developer docs
API playgroundTry for free, no card

Search company profiles

Vesalio

Full company profile

uuid00031wd

Namestring
Vesalio
Legal namestring
Vesalio
Websiteurl
vesalio.com
Company typeenum
Private
Founded yearint
2013
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersPlano, United States
HQ citystring
Plano
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
thrombectomy devices, mechanical thrombectomy, neurovascular stents, stroke treatment devices, vascular occlusion devices
Industry3 codes
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAE
Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKAIAG
Stroke & Vascular Neurology
NAICS code3 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Neurovascular Thrombectomy Devices
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Vesalio generates revenue through the sale of its proprietary thrombectomy devices including NeVa (neurovascular), enVast (coronary), and pVasc (peripheral). The company operates through direct sales teams in the U.S. and a network of exclusive distribution partners internationally. Products are sold to hospitals and medical centers for use in interventional procedures.

vesalio.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Operations, Personnel, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1NeVa
Description

Neurothrombectomy platform for acute ischemic stroke treatment featuring Drop Zone technology for first-pass success with all clot types.

vesalio.com
+4 more records
Core offering1 text field

Vesalio develops, manufactures, and commercializes proprietary mechanical thrombectomy devices for the treatment of vascular occlusions across neurovascular, coronary, and peripheral circulations. Its flagship products include NeVa (stroke thrombectomy), NeVa NET (stent retriever with integrated micro-filter), NeVa VS (post-aSAH cerebral vasospasm), enVast (coronary large thrombus burden), and pVasc (peripheral arterial occlusion). All products are built on the patented Drop Zone™ technology platform and are sold to hospitals and interventional specialists.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 90.7% substantial reperfusion within three passes (97/107 patients) in CLEAR study
+6 more records
Product overview1 text field

Vesalio is a medical device company offering a comprehensive thrombectomy platform with multiple specialized products targeting different vascular territories. The portfolio includes NeVa (neurothrombectomy for stroke), NeVa NET (with integrated distal micro-filter for embolic protection), NeVa VS (for cerebral vasospasm treatment), enVast (coronary thrombectomy), pVasc (peripheral vascular thrombectomy), and NeVaSC (aspiration catheters). All products share Vesalio's proprietary Drop Zone technology designed to capture and retain clots across the entire vasculature.

Product and service6 records
1NeVa Neurothrombectomy System
CategoryNeurovascular Thrombectomy Devices
Description

Multifunctional stent retriever neurothrombectomy device designed for first-pass success with all clot types in acute ischemic stroke treatment. Uses proprietary Drop Zone™ technology with multiple integrated capture zones to trap and retain thrombus. Available in multiple sizes including 3.0mm and 5.5mm diameters with varying Drop Zone configurations. Intended for hospitals and stroke centers performing endovascular procedures.

2NeVa NET (with Micro-Filter)
CategoryNeurovascular Thrombectomy Devices
Description

Stent retriever with the world's first and only micro-filter integrated in the distal tip, designed to maximize clot retention and prevent distal embolization during thrombectomy. Available in 4.0mm and 5.5mm sizes. Targets neurointerventionalists performing acute ischemic stroke procedures in hospitals and stroke centers.

3NeVa VS (Vasospasm Stent)
CategoryNeurovascular Devices
Description

FDA-approved retrievable nitinol stent specifically designed to treat cerebral vasospasm after aneurysmal subarachnoid hemorrhage (aSAH). Features smooth continuous architecture with enhanced outward radial force to dilate critically narrowed vessels. The only FDA-approved device for this indication. Targets neurosurgeons and neurointerventionalists at academic neuroscience centers.

4enVast Coronary Thrombectomy Device
CategoryCoronary Thrombectomy Devices
Description

Stent-based coronary thrombectomy device employing Drop Zone™ technology adapted for cardiac circulation to facilitate flow restoration in patients with large thrombus burden during primary PCI. First and only CE-approved and FDA-cleared large thrombus burden retriever for coronary arterial occlusion. Targets interventional cardiologists and PCI centers treating STEMI patients.

5pVasc Peripheral Thrombectomy System
CategoryPeripheral Vascular Thrombectomy Devices
Description

Mechanical thrombectomy system for peripheral arterial occlusion. Comprised of a self-expanding nitinol structure on a pusher wire designed for low profile and excellent deliverability in difficult peripheral anatomy. Indicated for non-surgical removal of occlusions from peripheral vasculature (arteries 2–6 mm in diameter). Targets vascular surgeons and interventional radiologists treating acute limb ischemia.

6NeVaSC Aspiration Catheter
CategoryAspiration Catheters
Description

Aspiration catheter for neurovascular and peripheral applications, with expanded indications for distal access with microcatheter delivery. Targets interventional neuroradiologists, neurointerventionalists, and vascular specialists performing thrombectomy procedures.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1J.D. McCulloch
Strategic tierCoreTypeOthers
Description

J.D. McCulloch serves as Chief Financial Officer overseeing all financial aspects of the business including finance, strategic planning and budgeting, cash management, and risk management. Brings over 25 years of professional experience spanning investment management, investment banking, business valuation, and corporate finance with focus on healthcare and biotech over the last decade.

vesalio.com
2Bob Bushok
Strategic tierCoreTypeOthers
Description

Bob Bushok serves as VP of U.S. Sales, leading the commercial expansion in the United States market. Previously appointed to build and manage the U.S. sales team in conjunction with NeVa VS product launch.

vesalio.com
3Gustavo Prado
Strategic tierCoreTypeOthers
Description

Gustavo Prado serves as VP of Development and Operations, overseeing product development and operational activities. Commented on publications regarding NET micro-filtration technology.

vesalio.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive distribution partner for Italy. National sales network trained and celebrating NeVa launch at company headquarters in Mirano near Venice. Dr. Massimo Sponza from Udine Hospital trained the team on acute ischemic stroke and thrombectomy.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Barcelona-based research institute that hosted Vesalio Clot Interaction Workshops where physicians from 8 different countries trained on NeVa Drop Zone Retrieval Technique. Used proprietary flow model for training sessions.

6Akpinar et al.
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration resulting in publication in Interventional Neuroradiology reporting remarkable first-pass recanalization rates in multi-center, real-life setting study of NeVa.

vesalio.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Published primary results from CLEAR study evaluating NeVa stent retriever for mechanical thrombectomy in acute ischemic stroke - a prospective multicenter FDA-regulated trial.

8VITAL Study Investigators
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical research collaboration resulting in publication in Journal of NeuroInterventional Surgery of VITAL trial demonstrating safety and efficacy of NeVa VS for treatment of symptomatic cerebral vasospasm following aSAH.

vesalio.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Inari Medical develops mechanical thrombectomy devices for venous thromboembolism and peripheral arterial disease (FlowTriever, ClotTriever), directly comparable to Vesalio's pVasc in the peripheral vascular space.

TypeBroad incumbent
Description

Medtronic's Solitaire stent retriever is a market-leading mechanical thrombectomy device for acute ischemic stroke. Medtronic also competes in peripheral and coronary vascular intervention, making it a broad incumbent across Vesalio's product territories.

TypeEmerging player
Description

Balt is a neurovascular-focused medical device company offering access catheters, coils, and thrombectomy-related products that compete with Vesalio's neurovascular portfolio in Europe and other markets.

TypeDirect peer
Description

Penumbra is a leading thrombectomy company with both neurovascular (Penumbra System, RED reperfusion catheters) and peripheral vascular product lines, making it the closest direct competitor across Vesalio's full neurovascular and peripheral vascular portfolio.

TypeBroad incumbent
Description

Stryker's Neurovascular division operates the Trevo stent retriever, one of the dominant devices in mechanical thrombectomy for acute ischemic stroke. As a large incumbent with a broad hospital footprint, Stryker competes directly with NeVa while also offering wider neurovascular portfolios.

TypeEmerging player
Description

Rapid Medical develops neurovascular devices including the Tigertriever stent retriever, a competitor in the mechanical thrombectomy space targeting similar acute ischemic stroke indications as Vesalio's NeVa.

TypeDirect peer
Description

AngioDynamics offers mechanical thrombectomy and peripheral vascular products (e.g., AlphaVac, Auryon) that overlap with Vesalio's pVasc peripheral system and aspiration catheter portfolio.

TypeEmerging player
Description

Acandis develops stent-based devices for neurovascular applications including thrombectomy and aneurysm treatment, partially overlapping with Vesalio's NeVa platform in stroke intervention.

9Johnson & Johnson (Cerenovus)
TypeBroad incumbent
Description

Cerenovus, J&J's neurovascular business, offers the Embotrap stent retriever and other thrombectomy devices directly competing with Vesalio's NeVa platform in acute ischemic stroke.

TypeBroad incumbent
Description

Terumo's neurovascular business offers access and aspiration products that intersect with Vesalio's aspiration catheter portfolio and broader neurovascular platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vesalio

Neurovascular Thrombectomy Devicesvesalio.com

Vesalio firmographics

Firmographics
Name
Vesalio
Legal name
Vesalio
Website
https://vesalio.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Vesalio industry classification

Industry
Product category
Neurovascular Thrombectomy Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAE
Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKAIAG
Stroke & Vascular Neurology

Keywords

  • Thrombectomy devices
  • Mechanical thrombectomy
  • Neurovascular stents
  • Stroke treatment devices
  • Vascular occlusion devices

Where Vesalio is headquartered

Location

Headquarters

HQ city
Plano
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Vesalio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

  1. Medical Device Sales: Vesalio generates revenue through the sale of its proprietary thrombectomy devices including NeVa (neurovascular), enVast (coronary), and pVasc (peripheral). The company operates through direct sales teams in the U.S. and a network of exclusive distribution partners internationally. Products are sold to hospitals and medical centers for use in interventional procedures.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels6 records

Vesalio product offering

Product offering

Core offering

Vesalio develops, manufactures, and commercializes proprietary mechanical thrombectomy devices for the treatment of vascular occlusions across neurovascular, coronary, and peripheral circulations. Its flagship products include NeVa (stroke thrombectomy), NeVa NET (stent retriever with integrated micro-filter), NeVa VS (post-aSAH cerebral vasospasm), enVast (coronary large thrombus burden), and pVasc (peripheral arterial occlusion). All products are built on the patented Drop Zone™ technology platform and are sold to hospitals and interventional specialists.

Product overview

Vesalio is a medical device company offering a comprehensive thrombectomy platform with multiple specialized products targeting different vascular territories. The portfolio includes NeVa (neurothrombectomy for stroke), NeVa NET (with integrated distal micro-filter for embolic protection), NeVa VS (for cerebral vasospasm treatment), enVast (coronary thrombectomy), pVasc (peripheral vascular thrombectomy), and NeVaSC (aspiration catheters). All products share Vesalio's proprietary Drop Zone technology designed to capture and retain clots across the entire vasculature.

Differentiator

Problem solved

Functional benefit

Brands

  • NeVa: Neurothrombectomy platform for acute ischemic stroke treatment featuring Drop Zone technology for first-pass success with all clot types.
  • NeVa NET
  • NeVa VS
  • enVast
  • pVasc

Products and services

  • NeVa Neurothrombectomy System Multifunctional stent retriever neurothrombectomy device designed for first-pass success with all clot types in acute ischemic stroke treatment. Uses proprietary Drop Zone™ technology with multiple integrated capture zones to trap and retain thrombus. Available in multiple sizes including 3.0mm and 5.5mm diameters with varying Drop Zone configurations. Intended for hospitals and stroke centers performing endovascular procedures.
  • NeVa NET (with Micro-Filter) Stent retriever with the world's first and only micro-filter integrated in the distal tip, designed to maximize clot retention and prevent distal embolization during thrombectomy. Available in 4.0mm and 5.5mm sizes. Targets neurointerventionalists performing acute ischemic stroke procedures in hospitals and stroke centers.
  • NeVa VS (Vasospasm Stent) FDA-approved retrievable nitinol stent specifically designed to treat cerebral vasospasm after aneurysmal subarachnoid hemorrhage (aSAH). Features smooth continuous architecture with enhanced outward radial force to dilate critically narrowed vessels. The only FDA-approved device for this indication. Targets neurosurgeons and neurointerventionalists at academic neuroscience centers.
  • enVast Coronary Thrombectomy Device Stent-based coronary thrombectomy device employing Drop Zone™ technology adapted for cardiac circulation to facilitate flow restoration in patients with large thrombus burden during primary PCI. First and only CE-approved and FDA-cleared large thrombus burden retriever for coronary arterial occlusion. Targets interventional cardiologists and PCI centers treating STEMI patients.
  • pVasc Peripheral Thrombectomy System Mechanical thrombectomy system for peripheral arterial occlusion. Comprised of a self-expanding nitinol structure on a pusher wire designed for low profile and excellent deliverability in difficult peripheral anatomy. Indicated for non-surgical removal of occlusions from peripheral vasculature (arteries 2–6 mm in diameter). Targets vascular surgeons and interventional radiologists treating acute limb ischemia.
  • NeVaSC Aspiration Catheter Aspiration catheter for neurovascular and peripheral applications, with expanded indications for distal access with microcatheter delivery. Targets interventional neuroradiologists, neurointerventionalists, and vascular specialists performing thrombectomy procedures.

Quantifiable outcome

  • 90.7% substantial reperfusion within three passes (97/107 patients) in CLEAR study
  • +6 more outcomes

Companies that use Vesalio

Customer profile

Named customers9 records

Segments4 records

Ideal customer profiles4 records

Vesalio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Vesalio partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core.

  • J.D. McCullochcoreOthersJ.D. McCulloch serves as Chief Financial Officer overseeing all financial aspects of the business including finance, strategic planning and budgeting, cash management, and risk management. Brings over 25 years of professional experience spanning investment management, investment banking, business valuation, and corporate finance with focus on healthcare and biotech over the last decade.
  • Bob BushokcoreOthersBob Bushok serves as VP of U.S. Sales, leading the commercial expansion in the United States market. Previously appointed to build and manage the U.S. sales team in conjunction with NeVa VS product launch.
  • Gustavo PradocoreOthersGustavo Prado serves as VP of Development and Operations, overseeing product development and operational activities. Commented on publications regarding NET micro-filtration technology.
  • Vassa MedicalcoreChannel Partner/ Reseller/ DistributorExclusive distribution partner for Italy. National sales network trained and celebrating NeVa launch at company headquarters in Mirano near Venice. Dr. Massimo Sponza from Udine Hospital trained the team on acute ischemic stroke and thrombectomy.
  • Vall d'Hebron Research InstitutecoreStrategic or Co-development PartnerBarcelona-based research institute that hosted Vesalio Clot Interaction Workshops where physicians from 8 different countries trained on NeVa Drop Zone Retrieval Technique. Used proprietary flow model for training sessions.
  • Akpinar et al.coreStrategic or Co-development PartnerResearch collaboration resulting in publication in Interventional Neuroradiology reporting remarkable first-pass recanalization rates in multi-center, real-life setting study of NeVa.
  • BMJ (British Medical Journal)coreStrategic or Co-development PartnerPublished primary results from CLEAR study evaluating NeVa stent retriever for mechanical thrombectomy in acute ischemic stroke - a prospective multicenter FDA-regulated trial.
  • VITAL Study InvestigatorscoreStrategic or Co-development PartnerClinical research collaboration resulting in publication in Journal of NeuroInterventional Surgery of VITAL trial demonstrating safety and efficacy of NeVa VS for treatment of symptomatic cerebral vasospasm following aSAH.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Vesalio competitors and assessment

Company assessment

Direct peers

  • Inari Medical: Inari Medical develops mechanical thrombectomy devices for venous thromboembolism and peripheral arterial disease (FlowTriever, ClotTriever), directly comparable to Vesalio's pVasc in the peripheral vascular space.
  • Penumbra: Penumbra is a leading thrombectomy company with both neurovascular (Penumbra System, RED reperfusion catheters) and peripheral vascular product lines, making it the closest direct competitor across Vesalio's full neurovascular and peripheral vascular portfolio.
  • AngioDynamics: AngioDynamics offers mechanical thrombectomy and peripheral vascular products (e.g., AlphaVac, Auryon) that overlap with Vesalio's pVasc peripheral system and aspiration catheter portfolio.

Broad incumbents

  • Medtronic: Medtronic's Solitaire stent retriever is a market-leading mechanical thrombectomy device for acute ischemic stroke. Medtronic also competes in peripheral and coronary vascular intervention, making it a broad incumbent across Vesalio's product territories.
  • Stryker (Neurovascular): Stryker's Neurovascular division operates the Trevo stent retriever, one of the dominant devices in mechanical thrombectomy for acute ischemic stroke. As a large incumbent with a broad hospital footprint, Stryker competes directly with NeVa while also offering wider neurovascular portfolios.
  • Johnson & Johnson (Cerenovus): Cerenovus, J&J's neurovascular business, offers the Embotrap stent retriever and other thrombectomy devices directly competing with Vesalio's NeVa platform in acute ischemic stroke.
  • Terumo (Neurovascular): Terumo's neurovascular business offers access and aspiration products that intersect with Vesalio's aspiration catheter portfolio and broader neurovascular platform.

Emerging players

  • Balt: Balt is a neurovascular-focused medical device company offering access catheters, coils, and thrombectomy-related products that compete with Vesalio's neurovascular portfolio in Europe and other markets.
  • Rapid Medical: Rapid Medical develops neurovascular devices including the Tigertriever stent retriever, a competitor in the mechanical thrombectomy space targeting similar acute ischemic stroke indications as Vesalio's NeVa.
  • Acandis: Acandis develops stent-based devices for neurovascular applications including thrombectomy and aneurysm treatment, partially overlapping with Vesalio's NeVa platform in stroke intervention.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Vesalio social profiles

Digital presence

Vesalio compliance and trust

Trust signal

Compliance8 records

Vesalio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vesalio leadership team

Management profile

Number of profiles

Profiles6 records

Vesalio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vesalio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vesalio

What does Vesalio do?

Vesalio develops, manufactures, and commercializes proprietary mechanical thrombectomy devices for the treatment of vascular occlusions across neurovascular, coronary, and peripheral circulations. Its flagship products include NeVa (stroke thrombectomy), NeVa NET (stent retriever with integrated micro-filter), NeVa VS (post-aSAH cerebral vasospasm), enVast (coronary large thrombus burden), and pVasc (peripheral arterial occlusion). All products are built on the patented Drop Zone™ technology platform and are sold to hospitals and interventional specialists.

Is Vesalio a public or private company?

Vesalio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Vesalio founded?

Vesalio was founded in 2013. It employs 51 to 100 people.

Where is Vesalio based?

Vesalio is headquartered in Plano, United States, in the North America region.

How does Vesalio make money?

One revenue line is on record: medical Device Sales.

Who are Vesalio's main competitors?

Direct peers on record are Inari Medical, Penumbra and AngioDynamics. Broad incumbents are Medtronic, Stryker (Neurovascular), Johnson & Johnson (Cerenovus) and Terumo (Neurovascular). Emerging players are Balt, Rapid Medical and Acandis.

Does Vesalio have an API?

No public API is recorded for Vesalio.

What industry is Vesalio in?

Vesalio's product category is Neurovascular Thrombectomy Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices, with a secondary code of HLAHAFAE, Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Medical BuyerVesalio appoints Daniel Davis to its boardVesalio appointed Daniel Davis to its Board of Directors and as Advisor to the CEO. Davis brings over 25 years of experience, including leadership at Penumbra and Imperative Care, and will guide product and commercial strategy. The appointment follows the published NATURE RCT data on Vesalio's enVast coronary thrombectomy technology.citybizVesalio Appoints Daniel Davis to Board to Advance Vascular Device GrowthVesalio appointed Daniel Davis to its board and as CEO advisor, adding a former Penumbra and Imperative Care executive with over 25 years of medical device experience. The appointment follows positive clinical data from the NATURE trial evaluating its enVast coronary thrombectomy technology. Davis will help advance commercialization across coronary, neurovascular, and peripheral vascular markets.PR NewswireVesalio Appoints Daniel Davis to Its Board of Directors and as Advisor to the CEOVesalio appointed Daniel Davis to its Board of Directors and as Advisor to the CEO. Davis brings over 25 years of experience, including roles at Penumbra and Imperative Care, and will guide product and commercial strategy. The appointment follows the published NATURE RCT data on Vesalio's enVast coronary thrombectomy technology.Mpo-magFormer Philips Executive Named Chief Commercial Officer at VesalioVesalio appointed Greg Cook as chief commercial officer, leading commercial strategy and sales. Cook previously served as senior vice president of sales at Philips Image Guided Therapy Devices. He will support Vesalio's thrombectomy platform expansion across neurovascular, coronary, and peripheral markets.Medical Device NetworkVesalio’s NATURE trial of enVast achieves primary endpointVesalio's NATURE trial met its primary endpoint, showing a nearly 26% reduction in infarct size with enVast versus standard care in STEMI patients. Secondary CMR data showed a 25% relative reduction, and safety outcomes favored enVast, with no strokes or deaths in the treatment arm.BioSpaceNATURE Randomized Controlled Trial Meets Primary Endpoint Evaluating enVast-Assisted Mechanical Thrombectomy in Large-Thrombus STEMIVesalio announced NATURE trial results at ESC Congress 2026, showing enVast-assisted thrombectomy reduced infarct size by nearly 26% versus standard PCI in STEMI patients with large thrombus burden. The 30-day safety profile was favorable, with no strokes or deaths in the enVast arm. The findings support selective use of mechanical thrombectomy in this patient group.AInvestZylo Ecosystem Navigates Market Noise Amid Divergent Corporate MilestonesAn Ainvest Coin Buzz report notes that the Zylo Ecosystem (ZYLO) shows no direct link to recent corporate announcements in biotech, decentralized lending and industrial technology. It cites LemLoans' $25 million funding and Gulf endorsement, Vesalio's enVast trial success, Kewaunee Scientific's $282 million revenue record, and ZCZL's interim results. The article advises investors to isolate ZYLO-specific catalysts from unrelated sector news.AijournNATURE Randomized Controlled Trial Meets Primary Endpoint Evaluating enVast-Assisted Mechanical Thrombectomy in Large-Thrombus STEMIVesalio announced results from the NATURE trial, a prospective, randomized, multi-center study of the enVast coronary clot retriever as an adjunctive reperfusion strategy in STEMI patients with large thrombus burden undergoing primary PCI. The primary endpoint showed enVast reduced infarct size by nearly 26% versus standard of care (p 0.001) by CK-MB area-under-the-curve, with no strokes or deaths in the enVast arm versus 1.3% and 2.6% in control.PR NewswireNATURE Randomized Controlled Trial Meets Primary Endpoint Evaluating enVast-Assisted Mechanical Thrombectomy in Large-Thrombus STEMIVesalio announced results from the NATURE trial, a prospective, randomized, multi-center study of the enVast coronary clot retriever as an adjunctive reperfusion strategy in STEMI patients with large thrombus burden undergoing primary PCI. The primary endpoint showed enVast reduced infarct size by nearly 26% versus standard of care (p 0.001) by CK-MB area-under-the-curve, with no strokes or deaths in the enVast arm versus 1.3% and 2.6% in control.MorningstarNATURE Randomized Controlled Trial Meets Primary Endpoint Evaluating enVast-Assisted Mechanical Thrombectomy in Large-Thrombus STEMIThe NATURE trial, a randomized controlled study of enVast-assisted mechanical thrombectomy in STEMI patients with large thrombus burden, met its primary endpoint. enVast reduced infarct size by nearly 26% compared with standard PCI, with no strokes and lower major adverse events. The results were presented at the 2026 ESC Congress.